Kiniksa Pharmaceuticals Ltd’s filing revealed that its CHAIRMAN & CEO Patel Sanj K unloaded Company’s shares for reported $1.37 million on Mar 07 ’24. In the deal valued at $21.02 per share,65,012 shares were sold. As a result of this transaction, Patel Sanj K now holds 0 shares worth roughly $0.0.
Then, Patel Sanj K sold 5,582 shares, generating $117,222 in total proceeds. Upon selling the shares at $21.00, the CHAIRMAN & CEO now owns 65,012 shares.
Before that, Patel Sanj K sold 12,742 shares. Kiniksa Pharmaceuticals Ltd shares valued at $273,834 were divested by the CHAIRMAN & CEO at a price of $21.49 per share. As a result of the transaction, Patel Sanj K now holds 70,594 shares, worth roughly $1.44 million.
Wells Fargo initiated its Kiniksa Pharmaceuticals Ltd [KNSA] rating to an Overweight in a research note published on May 03, 2024; the price target was $34. A number of analysts have revised their coverage, including BofA Securities’s analysts, who remained covering the stock and in late June has reiterated a ‘”a Buy”‘ rating for it. BofA/Merrill began covering KNSA with “Buy” recommendation on April 01, 2020. Barclays started covering the stock on March 11, 2019. It rated KNSA as “an Overweight”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals Ltd [NASDAQ:KNSA] saw its stock jump 1.70% to $20.33. Over the last five days, the stock has gained 8.60%. Kiniksa Pharmaceuticals Ltd shares have risen nearly 15.91% since the year began. Nevertheless, the stocks have risen 48.50% over the past one year. While a 52-week high of $22.09 was reached on 03/04/24, a 52-week low of $12.94 was recorded on 04/19/24. SMA at 50 days reached $19.17, while 200 days put it at $17.88. A total of 0.3 million shares were traded, compared to the trading of 0.4 million shares in the previous session.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 20.03, which if violated will result in even more drops to 19.72. On the upside, there is a resistance level at 20.54. A further resistance level may holdings at 20.74. The Relative Strength Index (RSI) on the 14-day chart is 70.59, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.68, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.84%. Stochastics %K at 92.72% indicates the stock is a selling.
The most recent change occurred on December 12, 2018 when Wedbush resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $33.
